Show simple item record

dc.contributor.authorRabago, D.en_US
dc.contributor.authorBest, T.en_US
dc.contributor.authorZgierska, A.en_US
dc.contributor.authorZeisig, E.en_US
dc.contributor.authorRyan, M.en_US
dc.contributor.authorCrane, D.en_US
dc.date.accessioned2017-05-03T16:06:29Z
dc.date.available2017-05-03T16:06:29Z
dc.date.issued2009en_US
dc.date.modified2012-05-15T22:22:14Z
dc.identifier.issn03063674en_US
dc.identifier.doi10.1136/bjsm.2008.052761en_US
dc.identifier.urihttp://hdl.handle.net/10072/41932
dc.description.abstractObjective: To appraise existing evidence for prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injection therapies for lateral epicondylosis (LE). Design: Systematic review. Data sources: Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials, Allied and Complementary Medicine. Search strategy: names and descriptors of the therapies and LE. Study Selection: All human studies assessing the four therapies for LE. Main results: Results of five prospective case series and four controlled trials (three prolotherapy, two polidocanol, three autologous whole blood and one platelet-rich plasma) suggest each of the four therapies is effective for LE. In follow-up periods ranging from 9 to 108 weeks, studies reported sustained, statistically significant (p<0.05) improvement in visual analogue scale primary outcome pain score measures and disease-specific questionnaires; relative effect sizes ranged from 51% to 94%; Cohen's d ranged from 0.68 to 6.68. Secondary outcomes also improved, including biomechanical elbow function assessment (polidocanol and prolotherapy), presence of abnormalities and increased vascularity on ultrasound (autologous whole blood and polidocanol). Subjects reported satisfaction with therapies on single-item assessments. All studies were limited by small sample size. Conclusions: There is strong pilot-level evidence supporting the use of prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections in the treatment of LE. Rigorous studies of sufficient sample size, assessing these injection therapies using validated clinical, radiological and biomechanical measures, and tissue injury/healing-responsive biomarkers, are needed to determine long-term effectiveness and safety, and whether these techniques can play a definitive role in the management of LE and other tendinopathies.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.format.extent236038 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherBMJ Groupen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom471en_US
dc.relation.ispartofpageto481en_US
dc.relation.ispartofissue7en_US
dc.relation.ispartofjournalBritish Journal of Sports Medicineen_US
dc.relation.ispartofvolume43en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchComplementary and Alternative Medicine not elsewhere classifieden_US
dc.subject.fieldofresearchRegenerative Medicine (incl. Stem Cells and Tissue Engineering)en_US
dc.subject.fieldofresearchSports Medicineen_US
dc.subject.fieldofresearchcode110499en_US
dc.subject.fieldofresearchcode100404en_US
dc.subject.fieldofresearchcode110604en_US
dc.titleA systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasmaen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright remains with the authors 2009. The attached file is reproduced here in accordance with the copyright policy of the publisher. For information about this journal please refer to the journal’s website or contact the authors.en_US
gro.date.issued2009
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record